Immuneering Co. (NASDAQ:IMRX) to Post Q2 2022 Earnings of ($0.52) Per Share, Oppenheimer Forecasts

Immuneering Co. (NASDAQ:IMRXGet Rating) – Equities researchers at Oppenheimer dropped their Q2 2022 EPS estimates for shares of Immuneering in a note issued to investors on Wednesday, May 11th. Oppenheimer analyst M. Breidenbach now expects that the company will post earnings of ($0.52) per share for the quarter, down from their previous forecast of ($0.46). Oppenheimer has a “Outperform” rating and a $25.00 price target on the stock. Oppenheimer also issued estimates for Immuneering’s Q3 2022 earnings at ($0.55) EPS, Q4 2022 earnings at ($0.58) EPS, FY2022 earnings at ($2.14) EPS, Q1 2023 earnings at ($0.61) EPS, Q2 2023 earnings at ($0.64) EPS, Q3 2023 earnings at ($0.65) EPS, Q4 2023 earnings at ($0.47) EPS, FY2023 earnings at ($2.32) EPS, FY2024 earnings at ($2.11) EPS, FY2025 earnings at ($2.40) EPS and FY2026 earnings at ($2.36) EPS.

Separately, Zacks Investment Research downgraded Immuneering from a “buy” rating to a “hold” rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $29.13.

NASDAQ IMRX opened at $5.03 on Monday. The stock’s 50 day moving average is $6.38 and its 200 day moving average is $13.32. Immuneering has a 12 month low of $4.11 and a 12 month high of $33.99. The stock has a market cap of $132.72 million and a PE ratio of -1.68.

Immuneering (NASDAQ:IMRXGet Rating) last released its quarterly earnings data on Thursday, March 10th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.03). The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.60 million. Immuneering had a negative return on equity of 38.00% and a negative net margin of 21.73%.

A number of large investors have recently bought and sold shares of IMRX. UBS Group AG purchased a new stake in shares of Immuneering in the 3rd quarter valued at $30,000. Citigroup Inc. purchased a new position in shares of Immuneering during the 3rd quarter worth approximately $33,000. New York State Common Retirement Fund purchased a new position in shares of Immuneering during the 3rd quarter worth approximately $45,000. American International Group Inc. raised its stake in shares of Immuneering by 111.1% during the 1st quarter. American International Group Inc. now owns 9,432 shares of the company’s stock worth $61,000 after buying an additional 4,964 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY purchased a new position in Immuneering in the 3rd quarter valued at approximately $75,000. Institutional investors own 47.41% of the company’s stock.

In related news, Director Ann E. Berman bought 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 15th. The shares were purchased at an average cost of $6.40 per share, with a total value of $38,400.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought 10,900 shares of company stock worth $73,621 over the last three months.

Immuneering Company Profile (Get Rating)

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.

See Also

Earnings History and Estimates for Immuneering (NASDAQ:IMRX)

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.